Clinical Trial Update: High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating high-dose intravenous immunoglobulin for spinocerebellar degeneration has completed its status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinocerebellar Degeneration

Drugs mentioned

• Intravenous Immunoglobulin (IVIG)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Spinocerebellar Degenerations | Phase 2 | Status: COMPLETED